基于人群的核心结合因子急性髓细胞白血病患者生存差异：SEER 数据库分析。
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.
机构信息
Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States; Dana Farber Cancer Institute, Boston, MA, United States.
Dana Farber Cancer Institute, Boston, MA, United States.
出版信息
Leuk Res. 2014 Jul;38(7):773-80. doi: 10.1016/j.leukres.2014.04.001. Epub 2014 Apr 12.
Abstract
We performed a retrospective population-based study using the SEER database to assess survival trends in CBF-AML between 2000 and 2010. Median OS increased from 16 months in 2000-2002 to 25 months in 2006-2008 (P=0.002). The 3-year OS rate for patients with inv(16) was 57.3%, but in t(8;21) was only 35.5%. Patients aged 75-84 had worse survival than patients aged 15-44 (HR 5.61, P=0.0002). Black race was associated with higher mortality (HR 1.50, P=0.03). Compared to clinical trial outcomes, CBF-AML survival is poorer in the general population, particularly among African Americans and the elderly, and in t(8;21) compared to inv(16) AML.
摘要
我们使用 SEER 数据库进行了一项回顾性基于人群的研究，以评估 2000 年至 2010 年 CBF-AML 的生存趋势。中位 OS 从 2000-2002 年的 16 个月增加到 2006-2008 年的 25 个月（P=0.002）。inv(16)患者的 3 年 OS 率为 57.3%，而 t(8;21)患者仅为 35.5%。75-84 岁的患者比 15-44 岁的患者生存更差（HR 5.61，P=0.0002）。黑人种族与更高的死亡率相关（HR 1.50，P=0.03）。与临床试验结果相比，CBF-AML 在普通人群中的生存率较差，尤其是在非裔美国人和老年人中，以及 t(8;21)与 inv(16)AML 相比。
相似文献
1
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.
Leuk Res. 2014 Jul;38(7):773-80. doi: 10.1016/j.leukres.2014.04.001. Epub 2014 Apr 12.
2
Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.
3
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
Blood. 2009 Feb 26;113(9):2096-103. doi: 10.1182/blood-2008-03-145862. Epub 2009 Jan 6.
4
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer. 2009 Jul 15;115(14):3217-21. doi: 10.1002/cncr.24367.
5
Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Ann Hematol. 2019 May;98(5):1135-1147. doi: 10.1007/s00277-019-03624-y. Epub 2019 Feb 13.
6
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Blood. 2011 Nov 17;118(20):5409-15. doi: 10.1182/blood-2011-07-364661. Epub 2011 Sep 26.
7
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
J Clin Oncol. 2009 Oct 1;27(28):4747-53. doi: 10.1200/JCO.2008.21.0674. Epub 2009 Aug 31.
8
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
Am J Hematol. 2014 Dec;89(12):1121-31. doi: 10.1002/ajh.23821. Epub 2014 Aug 27.
9
Nomogram models predicting prognosis for patients with t(8;21) acute myeloid leukemia: a SEER-based study.
Hematology. 2024 Dec;29(1):2381169. doi: 10.1080/16078454.2024.2381169. Epub 2024 Jul 24.
10
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Leuk Res. 2014 Dec;38(12):1435-40. doi: 10.1016/j.leukres.2014.09.017. Epub 2014 Oct 6.
引用本文的文献
1
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02596-0.
2
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Blood Adv. 2025 Feb 11;9(3):533-544. doi: 10.1182/bloodadvances.2024014127.
3
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy.
Haematologica. 2025 Mar 1;110(3):608-620. doi: 10.3324/haematol.2024.285448.
4
Improving long-term outcomes with intensive induction chemotherapy for patients with AML.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):175-185. doi: 10.1182/hematology.2023000504.
5
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Leukemia. 2023 Jun;37(6):1234-1244. doi: 10.1038/s41375-023-01884-2. Epub 2023 Apr 11.
6
How to Improve Prognostication in Acute Myeloid Leukemia with Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring.
Biomedicines. 2021 Aug 3;9(8):953. doi: 10.3390/biomedicines9080953.
7
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Leukemia. 2020 Dec;34(12):3161-3172. doi: 10.1038/s41375-020-0806-0. Epub 2020 Mar 30.
8
IL1RL1 is dynamically expressed on Cbfb-MYH11 leukemia stem cells and promotes cell survival.
Sci Rep. 2019 Feb 11;9(1):1729. doi: 10.1038/s41598-018-38408-3.
9
Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.
Ochsner J. 2017 Winter;17(4):398-404.
10
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e19-e25. doi: 10.1016/j.clml.2017.09.017. Epub 2017 Sep 25.
本文引用的文献
1
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Eur J Haematol. 2013 Sep;91(3):209-218. doi: 10.1111/ejh.12130. Epub 2013 Jul 25.
2
Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.
Cancer. 2013 Aug 1;119(15):2720-7. doi: 10.1002/cncr.28129. Epub 2013 Apr 30.
3
Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?
Am J Clin Oncol. 2015 Apr;38(2):159-64. doi: 10.1097/COC.0b013e31828d7536.
4
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.
Blood. 2013 Apr 11;121(15):2996-3004. doi: 10.1182/blood-2012-08-448068. Epub 2013 Feb 14.
5
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):153-8. doi: 10.1016/j.clml.2012.11.006. Epub 2012 Dec 21.
6
Survival for older patients with acute myeloid leukemia: a population-based study.
Haematologica. 2012 Dec;97(12):1916-24. doi: 10.3324/haematol.2012.066100. Epub 2012 Jul 6.
7
Acute myeloid leukemia in the real world: why population-based registries are needed.
Blood. 2012 Apr 26;119(17):3890-9. doi: 10.1182/blood-2011-12-379008. Epub 2012 Mar 1.
8
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
9
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.
Blood. 2012 Jan 5;119(1):34-43. doi: 10.1182/blood-2011-04-347872. Epub 2011 Nov 15.
10
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.
Blood. 2011 Aug 4;118(5):1248-54. doi: 10.1182/blood-2011-04-346437. Epub 2011 Jun 8.
Zotero 插件